The company reported revenue from operations at ₹1,000 crore, up 2.7%YoY over ₹973.6 crore reported in Q4 FY24.

Most of the IPO proceeds will be used for deleveraging, allowing for better margins and financial flexibility.

Headline CPI drops. There’s more to the story as core CPI remains elevated. Will RBI continue its accommodative stance as ...

The scope of works comprises survey, design, supply, installation, testing and commissioning of KAVACH equipment and any ...

On the operating front, EBITDA for the quarter was reported at ₹964 Crore. It was 9.20% higher than ₹883 in Q4FY24.

If you look at the 8 hybrid fund categories (including solution-oriented funds) across 12 months, then you have 96 data flow ...

Max Healthcare Institute announced a 21% year-on-year growth in its March quarter net profit at ₹376 Crore. The company ...

The issue may be done through public offers or private placements. This subject to market conditions, and regulatory ...

CORE SECTOR SUBDUED, AS REFINING HIT HARD. Core sector growth for April 2025 at 0.49% marked the lowest level in 8 months. It ...

This latest order enlarges TCS’s continued engagement with BSNL to modernise the state-run telecom operator’s mobile infrastructure.

As per the company’s filing with the bourses, Biocon Biologics has developed and manufactured this injection while Yoshindo Inc.

Operating margin of Abbott India significantly improved, widened by 434 bps to 26.7% in Q4 FY25 from 22.9% a year ago quarter ...